May 18, 2020
Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC(TM) ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
Feb 27, 2020
Nuvo Pharmaceuticals® Announces Health Canada Approves Suvexx(TM) For The Acute Treatment of Migraine
Oct 11, 2019
Lilly's REYVOW(TM) (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
Oct 02, 2019
Upsher-Smith Laboratories Launches Tosymra(TM) (sumatriptan) Nasal Spray For The Acute Treatment Of Migraine In Adults
Sep 26, 2019
Currax(TM) Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®
Jul 20, 2019
Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults
Jul 09, 2019
Allergan Continues to Demonstrate Leadership in Migraine with 29 Presentations at the 2019 American Headache Society Annual Meeting
Jun 27, 2018
Promius Pharma Announces Migraine Presentations at the 60th Annual Scientific Meeting of the American Headache Society
Nov 15, 2017
Promius Pharma Announces ZEMBRACE® SymTouch® (Sumatriptan Injection) 3 mg Achieves Primary Endpoint in Post-Approval Clinical Trial
Sep 19, 2017
New Review Provides an Overview of Triptans in the Treatment of Acute Migraine
Sep 07, 2017
Promius Pharma Presents Positive Results for Phase 2 Study of DFN-02, a Novel Intranasal Formulation of Sumatriptan, at 18th Congress of the International Headache Society
Jun 07, 2017
Promius Pharma Announces Positive Results for Phase 2 Study of DFN-02, a Novel Intranasal Formulation of Sumatriptan
Jun 07, 2017
Promius Pharma to Present Innovative Scientific Results From Migraine Studies at the 59th Annual Scientific Meeting of the American Headache Society